



MINUTES OF THE FRED HUTCHINSON CANCER CENTER INSTITUTIONAL BIOSAFETY COMMITTEE

June 29, 2026 Special IBC Meeting, 12:00 pm, MS Teams

ATTENDANCE

MEMBERS

<i>Present</i>	<i>Absent</i>	
☒	☐	Kevin Barry PhD, Public Health Sciences, <i>Member</i>
☒	☐	Elizabeth Cromwell, PDX Program Lead, <i>Member</i>
☐	☒	Bernadeta Dadonaite PhD, Staff Scientist, Basic Sciences, <i>Member</i>
☐	☒	Neelendu Dey MD, PhD, Clinical Research Division, <i>Member</i>
☐	☒	Michael Emerman PhD, Human Biology, <i>Member</i>
☒	☐	Marian Esvelt DVM, Associate Director, Comparative Medicine, <i>Member</i>
☐	☒	Taran Gujral PhD, Human Biology, <i>Member</i>
☒	☐	Tony Han, BSL-3/ABSL-3 Facility Manager, <i>Member</i>
☐	☒	Alexandre Hirayama MD, Clinical Research Division, <i>Member</i>
☒	☐	Keith Jerome MD, PhD, Vaccine and Infectious Disease, <i>Chairperson</i>
☒	☐	Michelle Kom-Gochmour MN, RN, COHN-S, <i>Community Member</i>
☒	☐	John McNevin MSc, Program Manager, Vaccine and Infectious Disease, <i>Member</i>
☒	☐	Jacqui Murray-Wijelath PhD, <i>Community Member</i>
☒	☐	Susan Parazzoli MS, RBP, Biosafety Officer, <i>Member</i>
☒	☐	Stefan Radtke PhD, Staff Scientist, Translational Science & Therapeutics, <i>Member</i>
☒	☐	Joshua Schiffer MD, MSc, Clinical Researcher, <i>Member</i>
☐	☒	Shivani Srivastava PhD, Clinical Research Division, <i>Member</i>
☒	☐	Susan Strenk, Research Technician IV, Vaccine and Infectious Disease, <i>Member</i>
☒	☐	Andrea Towler MSc, <i>Community Member</i>
☐	☒	Allison Zelikoff MN, RN, COHN-S, Occupational Health Manager, <i>Member</i>

NON-MEMBERS

Dagmar Achtelik, Administrative Coordinator, EH&S, *Committee Secretary*
 Jake White, Assistant Biosafety Officer, Environmental Health & Safety
 Cindy Wladyka, EH&S Specialist for Biosafety, Environmental Health & Safety

VISITORS

None

Dr. Jerome, Chairperson, called the meeting to order at 12:00 pm.

I. ANNOUNCEMENTS AND UPDATES

- None

II. REMINDER FOR CONFLICT OF INTEREST

The chair reminded the committee that the NIH Guidelines, Section IV-B-2-a-(4) states: "No member of an Institutional Biosafety Committee may be involved (except to provide information requested by the Institutional Biosafety Committee) in the review or approval of a project in which he/she has been or expects to be engaged or has a direct financial interest."

III. MINUTES

None

IV. REVIEW OF ACTION ITEMS

None

V. NEW BUSINESS**HUMAN GENE TRANSFER APPLICATIONS**

Principal Investigator:	RG #:	Biosafety Level:	NIH Sections:
King	RG1126477	BSL-2 (preparation) Standard precautions (administration)	III-C
Summary (including agents, manipulations, genes, hosts, proposed containment/biosafety levels):			
The Investigational Drug Product (IDP) for this trial is two DNA plasmids. One is customized for each patient based on their unique mutations (neoantigens) found on the tumor and the other encodes the molecular adjuvant IL-12. These are being administered for the treatment of liver cancer. Plasmids are manufactured offsite by the Sponsor. Formulations are received by IDS and prepared for injection in the Fred Hutch IV Room Pharmacy at BSL-2. Prepared syringes are transported by Fred Hutch internal couriers to the Prevention Center for administration under standard precautions. Plasmids will be administered intradermally followed by electroporation. There will be no integration or modification of host genome. Safety of the neoantigen is not possible to fully determine because they are personalized, but this IDP is generally low risk due to being non-integrating and transiently expressed.			
Comments & Discussion:			
The Committee reviewed this work and confirmed the research is clearly described, the associated risks recognized, and appropriate biosafety practices implemented in accordance with institutional and regulatory standards.			
Training & Facilities:		Vote & Recusals:	
Facilities have been inspected and are appropriate. Study PI training is up-to-date and complete.		Approved unanimously	

CATEGORY "A" IBC REVIEWS

None

CATEGORY "B" IBC REVIEWS

None

CATEGORY "C" BSO REVIEWS

None

EMUA CLOSEOUTS

None

UPDATES/PROGRAM REVIEW

None

INCIDENTS, ACCIDENTS, AND PROBLEMS

None


VI. OTHER BUSINESS

None

Meeting adjourned at 12:07 pm.

Signed by:

CB83B35EA7A9430...
Keith Jerome, MD PhD
Vaccine and Infectious Disease
Institutional Biosafety Committee Chairperson

DocuSigned by:

09CC928C5E494BB...
Susan Parazzoli MS, RBP
Biosafety Officer

cc: Dr. Thomas J. Lynch, President, and Director
Dr. Nicole (Niki) Robinson, Chief Administrative Officer